Acetyl-HMGB1 (K12) Antibody

What is Acetyl-High mobility group box 1 (Lys12) and its significance in cellular signaling?

Acetyl-High mobility group box 1 (Lys12) represents a post-translationally modified form of the High mobility group box 1 protein where lysine 12 has undergone acetylation. This specific modification plays a crucial role in determining the protein's subcellular localization and function. When High mobility group box 1 protein is acetylated at key lysine residues, particularly within its nuclear localization signals (NLS), it translocates from the nucleus to the cytoplasm and can be subsequently released extracellularly, where it functions as a danger-associated molecular pattern (DAMP) .

Acetylation at lysine 12 specifically has been identified as a critical modification that promotes the active release of High mobility group box 1 protein from activated monocytes, macrophages, and potentially other cell types . This acetylated form serves as a biomarker for various pathological conditions, most notably in mesothelioma patients, where serum levels of acetylated High mobility group box 1 protein are significantly elevated .

What experimental applications are validated for the Acetyl-High mobility group box 1 (Lys12) antibody?

The Acetyl-High mobility group box 1 (Lys12) antibody has been validated for multiple experimental applications in research settings:

This antibody recognizes acetylated High mobility group box 1 at lysine 12 specifically across multiple species including human, mouse, and rat . The antibody is typically available in a purified format in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide, with a standard concentration of 1 mg/mL .

How can researchers optimize detection of acetylated High mobility group box 1 in subcellular fractionation experiments?

For optimal detection of acetylated High mobility group box 1 in subcellular fractionation experiments, researchers should:

• Isolation Protocol: Employ a gentle cell lysis procedure to separate nuclear and cytoplasmic fractions while preserving protein modifications. The nuclear-cytoplasmic fractionation should be performed with buffers containing deacetylase inhibitors (e.g., trichostatin A, nicotinamide) to prevent deacetylation during sample processing .

• Western Blot Analysis: After fractionation, perform immunoblotting using the Acetyl-High mobility group box 1 (Lys12) antibody (typically at 1:1000 dilution). Include proper loading controls for both nuclear (e.g., lamin B) and cytoplasmic (e.g., GAPDH) fractions .

• Quantification: Normalize the acetylated High mobility group box 1 signal to total High mobility group box 1 protein levels to accurately assess the proportion of acetylated protein rather than changes in total protein expression .

• Verification Controls: Include positive controls such as cells treated with histone deacetylase inhibitors (e.g., SAHA) which increase High mobility group box 1 acetylation, and negative controls such as cells overexpressing histone deacetylase 1, which reduces High mobility group box 1 acetylation .

Studies have shown that subcellular fractionation followed by western blotting can effectively demonstrate increased cytoplasmic localization of acetylated High mobility group box 1 in cells with reduced BRCA1-associated protein 1 levels compared to controls .

What is the mechanistic relationship between BRCA1-associated protein 1, Histone deacetylase 1, and High mobility group box 1 acetylation?

The interaction between BRCA1-associated protein 1, Histone deacetylase 1, and High mobility group box 1 forms a regulatory trimer that controls High mobility group box 1 acetylation status and subsequent release. The mechanism involves:

• Complex Formation: BRCA1-associated protein 1 interacts directly with both High mobility group box 1 and Histone deacetylase 1, forming a trimeric complex. Surface plasmon resonance studies have demonstrated that BRCA1-associated protein 1 binds to High mobility group box 1 with high affinity (KD = 3.8 ± 1.5 nM) and to Histone deacetylase 1 with KD = 17.1 ± 7.7 nM .

• Deubiquitylation Activity: BRCA1-associated protein 1 deubiquitylates and stabilizes Histone deacetylase 1, preventing its degradation. This stabilized Histone deacetylase 1 then deacetylates High mobility group box 1, particularly at lysine 12 .

• Nuclear Retention: When deacetylated by Histone deacetylase 1, High mobility group box 1 is retained in the nucleus. Reduced BRCA1-associated protein 1 levels lead to increased Histone deacetylase 1 degradation, resulting in High mobility group box 1 hyperacetylation and subsequent extracellular release .

• Complex Stability: The preformed BRCA1-associated protein 1-Histone deacetylase 1 complex binds to High mobility group box 1 with exceptional affinity (KD = 1.2 ± 0.7 nM), which is significantly higher than the affinity of free Histone deacetylase 1 for High mobility group box 1 (KD = 24.1 ± 14.4 nM) .

This mechanistic relationship explains why BRCA1-associated protein 1 mutations lead to increased extracellular levels of acetylated High mobility group box 1, which promotes inflammation and potentially contributes to mesothelioma development.

How can Acetyl-High mobility group box 1 (Lys12) antibody be used as a diagnostic tool for mesothelioma in BRCA1-associated protein 1 mutation carriers?

The Acetyl-High mobility group box 1 (Lys12) antibody shows promise as a diagnostic tool for mesothelioma detection in BRCA1-associated protein 1 mutation carriers through several methodological approaches:

• Serum Biomarker Analysis: Immunoblot analysis of serum samples using this antibody can detect both total and acetylated High mobility group box 1 levels. Studies have shown that BRCA1-associated protein 1 mutation carriers have slightly elevated baseline levels of acetylated High mobility group box 1 compared to wild-type individuals, but these levels increase dramatically upon mesothelioma development .

• Longitudinal Monitoring: Sequential serum measurements in BRCA1-associated protein 1 mutation carriers can track changes in acetylated High mobility group box 1 levels over time. A significant case study demonstrated that a BRCA1-associated protein 1 mutation carrier in remission from mesothelioma showed moderate elevation in acetylated High mobility group box 1, but levels increased dramatically upon disease relapse 10 years later .

• Mouse Model Validation: The diagnostic value has been validated in BRCA1-associated protein 1 heterozygous mouse models, where serum levels of acetylated High mobility group box 1 increased moderately upon asbestos exposure but increased dramatically when mice developed mesothelioma .

The table below summarizes the relative serum levels of acetylated High mobility group box 1 in different clinical scenarios:

These findings suggest that monitoring acetylated High mobility group box 1 levels using specific antibodies could serve as a valuable biomarker for early detection and disease monitoring in high-risk populations.

What methods are most effective for quantifying extracellular High mobility group box 1 in experimental systems?

Several validated methods can be employed for the accurate quantification of extracellular High mobility group box 1 in experimental systems:

• Enzyme-Linked Immunosorbent Assay (ELISA):

  • Most widely used method for quantifying High mobility group box 1 in cell culture supernatants and biological fluids

  • Commercial ELISA kits specifically detecting acetylated High mobility group box 1 at lysine 12 are available

  • Can detect concentration changes in conditioned media from cells with different BRCA1-associated protein 1 expression levels

  • Sensitivity typically in the range of 10-100 pg/mL depending on the kit

• Immunoblot Analysis:

  • Can simultaneously detect acetylated High mobility group box 1 and total High mobility group box 1

  • Requires concentration of cell culture supernatants through methods such as TCA precipitation

  • Useful for confirming ELISA results and examining specific High mobility group box 1 modifications

  • Less quantitative than ELISA but provides information about molecular weight and protein integrity

• In Vivo Plasma Sampling:

  • Animal models can be used to measure the kinetics of High mobility group box 1 release following various treatments

  • Requires careful timing of blood collection (studies show significant time-dependent increases after treatment)

  • Necessary to use EDTA-coated collection tubes and process samples rapidly to prevent ex vivo modifications

Studies have demonstrated that ELISA can effectively detect increased High mobility group box 1 levels in conditioned media from BRCA1-associated protein 1-silenced cells compared to control cells, as well as in the plasma of mice treated with various pharmacological agents known to induce High mobility group box 1 release .

How do epigenetic modifiers affect High mobility group box 1 acetylation and release in experimental systems?

Epigenetic modifiers have significant effects on High mobility group box 1 acetylation and release through several mechanisms:

• Histone Deacetylase Inhibitors:

  • SAHA (Vorinostat) treatment causes strong nucleo-cytoplasmic translocation of High mobility group box 1

  • Leads to dose-dependent release of High mobility group box 1 into cell culture supernatant

  • Increases plasma concentration of High mobility group box 1 when administered in vivo

  • Mechanism involves inhibition of histone deacetylases, preventing deacetylation of High mobility group box 1

• DNA Methyltransferase Inhibitors:

  • Azacitidine and decitabine induce significant High mobility group box 1 release

  • High-content screening identified these agents as potent inducers of High mobility group box 1 translocation

  • Both compounds increase cytoplasmic High mobility group box 1 and cause time-dependent elevation in plasma High mobility group box 1 levels in mice

• Combined Epigenetic Therapy Effects:

  • Epigenetic drugs can act synergistically to enhance High mobility group box 1 release

  • These agents often promote immunogenic cell death, where High mobility group box 1 release is a key component

  • Research shows that these compounds increase both total and acetylated High mobility group box 1 in cell culture supernatants and in vivo

These findings suggest that epigenetic modifiers may be used experimentally to manipulate High mobility group box 1 acetylation and release, providing tools for studying the biology of High mobility group box 1 and potentially developing therapeutic strategies targeting High mobility group box 1-dependent pathways.

What experimental design considerations are important when studying Acetyl-High mobility group box 1 (Lys12) in mesothelioma models?

When designing experiments to study Acetyl-High mobility group box 1 (Lys12) in mesothelioma models, researchers should consider several critical factors:

• Model Selection:

  • Cell lines: Use both BRCA1-associated protein 1 wild-type and BRCA1-associated protein 1-mutant or BRCA1-associated protein 1-silenced mesothelioma cells

  • Primary cells: Consider using primary human mesothelial cells with BRCA1-associated protein 1 knockdown

  • Animal models: BRCA1-associated protein 1 heterozygous mice exposed to asbestos provide relevant in vivo systems

• Asbestos Exposure Protocol:

  • In vitro: Human mesothelial cells exposed to crocidolite asbestos (typical dose: 1-5 μg/cm²) in the presence of tumor necrosis factor-alpha (10 ng/mL) can be used to study transformation

  • In vivo: Intraperitoneal injection of asbestos fibers (typically 400 μg per mouse) in BRCA1-associated protein 1 heterozygous mice

• BRCA1-associated protein 1 Manipulation Approaches:

  • siRNA for transient knockdown (typically 20-50 nM)

  • shRNA for stable knockdown

  • CRISPR/Cas9 for gene editing to introduce specific mutations found in mesothelioma patients

  • Adenoviral vectors for overexpression of wild-type or mutant BRCA1-associated protein 1

• High mobility group box 1 Inhibition Strategies:

  • Pharmacological inhibitors: Box A (antagonist of High mobility group box 1), ethyl pyruvate, or aspirin

  • Aspirin has been shown to decrease secretion of acetylated High mobility group box 1 in BRCA1-associated protein 1-silenced cells

• Readouts and Endpoints:

  • In vitro transformation: Measure foci formation in human mesothelial cells exposed to asbestos and tumor necrosis factor-alpha

  • High mobility group box 1 acetylation: Immunoprecipitation with High mobility group box 1 antibody followed by acetyl-lysine detection

  • High mobility group box 1 localization: Subcellular fractionation or immunofluorescence

  • High mobility group box 1 release: ELISA of conditioned media or serum

Research has demonstrated that BRCA1-associated protein 1-silenced human mesothelial cells show increased foci formation when exposed to asbestos and tumor necrosis factor-alpha, and this effect can be reduced by High mobility group box 1 inhibitors such as BoxA, ethyl pyruvate, or aspirin .

How can researchers distinguish between passive release and active secretion of High mobility group box 1?

Distinguishing between passive release (from damaged/dying cells) and active secretion of High mobility group box 1 is crucial for interpreting experimental results. The following methodological approaches can be employed:

• Cell Viability Assessment:

  • Concurrent measurement of cell death markers (LDH release, PI staining, TUNEL assay)

  • Comparison of High mobility group box 1 release kinetics with cell death markers

  • Active secretion typically precedes significant cell death, while passive release correlates directly with cell death markers

• Acetylation Status Analysis:

  • Actively secreted High mobility group box 1 is typically hyperacetylated, particularly at lysine 12

  • Use of the Acetyl-High mobility group box 1 (Lys12) antibody to specifically detect this form

  • Calculating the ratio of acetylated to total High mobility group box 1 can help distinguish the mechanism

• Subcellular Localization Tracking:

  • Use of fluorescent protein-tagged High mobility group box 1 (e.g., GFP-HMGB1) to monitor localization

  • The "retention using selective hooks" (RUSH) system can be employed to track nuclear-to-cytoplasmic translocation

  • Active secretion involves a distinct pattern of nucleo-cytoplasmic translocation before release

• Inhibitor Studies:

  • Secretion pathways: Use of inhibitors of non-classical secretion pathways (e.g., methylamine, ABC transporter inhibitors)

  • Autophagy: Inhibitors like 3-methyladenine can block autophagy-dependent High mobility group box 1 secretion

  • These inhibitors should affect active secretion but not passive release

• Serum/Plasma Analysis:

  • Time-course analysis of High mobility group box 1 release in vivo

  • Active secretion typically shows a more regulated pattern

  • Analysis of other damage-associated molecular patterns (DAMPs) can help contextualize High mobility group box 1 findings

Research has demonstrated the utility of high-content screening methods to identify compounds that specifically induce High mobility group box 1 release, allowing for the identification of agents that promote either active secretion or passive release through different mechanisms .

What are effective strategies for validating High mobility group box 1 acetylation at lysine 12 in immunogenic cell death research?

Validating High mobility group box 1 acetylation at lysine 12 in immunogenic cell death research requires multiple complementary approaches:

• Antibody Validation:

  • Western blot with recombinant acetylated and non-acetylated High mobility group box 1 proteins

  • Peptide competition assays using synthesized acetyl-peptides derived from the N-terminal region of human High mobility group box 1 around lysine 12

  • Testing on samples from cells treated with known modulators of High mobility group box 1 acetylation (e.g., HDAC inhibitors)

• Mass Spectrometry Confirmation:

  • Immunoprecipitation of High mobility group box 1 followed by mass spectrometry

  • Site-specific identification of acetylation at lysine 12

  • Quantitative assessment of acetylation stoichiometry

• Genetic Approaches:

  • Use of lysine-to-arginine (K12R) or lysine-to-glutamine (K12Q) mutants

  • K12R prevents acetylation while K12Q mimics constitutive acetylation

  • Comparing wild-type and mutant High mobility group box 1 localization and release patterns

• Functional Validation:

  • Confirming immunogenic properties of released High mobility group box 1

  • Testing dendritic cell activation by conditioned media

  • In vivo vaccination studies using cancer cells treated with immunogenic cell death inducers

• Correlation with Immunogenic Cell Death Markers:

  • Simultaneous detection of other immunogenic cell death markers (calreticulin exposure, ATP release)

  • Time-course analysis to establish the sequence of events

  • Comparison between immunogenic and non-immunogenic cell death inducers